( Toronto:SHS )

News from sophiris bio, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 16, 2016, 16:01 ET Sophiris Bio Reports First Quarter 2016 Financial Results and Key Business Highlights

 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment...


May 12, 2016, 16:01 ET Sophiris Bio Engages Oppenheimer & Co. to Advise on Strategic Opportunities

 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment...


May 11, 2016, 16:01 ET Sophiris Bio Inc. Announces Closing of Public Offering of $5,000,000

 Sophiris Bio Inc. (Nasdaq: SPHS) today announced that it closed its previously announced public offering of common stock and warrants at $1.40...


May 06, 2016, 17:30 ET Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment...


May 05, 2016, 16:00 ET Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting

 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment...


Apr 28, 2016, 16:00 ET Sophiris Bio to Present at Bloom Burton & Co. Healthcare Investor Conference

 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment...


Mar 23, 2016, 16:01 ET Sophiris Bio Reports Fourth Quarter and Full Year 2015 Financial Results and Key Business Highlights

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of...


Feb 02, 2016, 16:01 ET Sophiris Bio to Present at BIO CEO & Investor Conference

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin for the treatment of urological...


Jan 28, 2016, 13:00 ET Sophiris Bio Reports Encouraging Preliminary Data from Phase 2a Proof of Concept Study in Localized Prostate Cancer

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of...


Nov 16, 2015, 16:01 ET Sophiris Bio Reports Third Quarter Financial Results and Business Highlights

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of...


Nov 10, 2015, 08:18 ET Sophiris Bio Phase 3 BPH Study Successfully Meets Primary Endpoint

 Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment...


Sep 05, 2013, 17:00 ET Sophiris Bio to Present at the Stifel Healthcare Conference

SAN DIEGO AND VANCOUVER, Sept. 5, 2013 /PRNewswire/ - Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a...


Aug 23, 2013, 09:38 ET Sophiris Bio Closes $65 Million Public Offering

SAN DIEGO and VANCOUVER, Aug. 23, 2013 /PRNewswire/ - Sophiris Bio Inc. (NASDAQ: SPHS, TSX: SHS) (the "Company" or "Sophiris"), a...


Aug 16, 2013, 09:28 ET Sophiris Bio Prices its Previously Announced Public Offering of Common Shares

SAN DIEGO and VANCOUVER, Aug. 16, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical...


Aug 12, 2013, 16:05 ET Sophiris Bio Announces Share Consolidation

Share Consolidation in Anticipation of Listing on the NASDAQ Stock Market SAN DIEGO AND VANCOUVER, Aug. 12, 2013 /PRNewswire/ - Sophiris Bio...


Aug 05, 2013, 17:28 ET Sophiris Bio Reports Second Quarter Financial Results and Recent Key Operational Highlights

SAN DIEGO AND VANCOUVER, Aug. 5, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical...


Jul 15, 2013, 07:00 ET Sophiris Bio Announces an Addition to its Board of Directors

SAN DIEGO, CA and VANCOUVER, July 15, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a...


Jul 12, 2013, 16:00 ET Sophiris Bio Announces Changes to Board of Directors

SAN DIEGO & VANCOUVER, July 12, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a biopharmaceutical...


Apr 30, 2013, 17:00 ET Sophiris Bio Reports First Quarter Financial Results and Recent Key Operational Highlights

SAN DIEGO, CA and VANCOUVER, April 30, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company" or "Sophiris"), a urology...


Feb 18, 2013, 15:35 ET Correction - Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ

This release has been updated to correct the expected start date of the first pivotal trial for PRX302 to "in the first half of 2013." SAND...


Feb 15, 2013, 17:24 ET Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ

SAN DIEGO, CA and VANCOUVER, BC, Feb. 15, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) ("Sophiris" or the "Company"), a...


Feb 13, 2013, 17:00 ET Sophiris Bio Reports Fourth Quarter and Year-End 2012 Financial Results and Key Operational Highlights

SAN DIEGO, CA and VANCOUVER, Feb. 13, 2013 /PRNewswire/ - Sophiris Bio Inc. (Sophiris, TSX: SHS) (the "Company"), a biopharmaceutical company...


Nov 12, 2012, 17:00 ET Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights

SAN DIEGO, CA and VANCOUVER, BC, Nov. 12, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX:SHS) ("Sophiris"), a urology company developing a...


Nov 06, 2012, 16:00 ET Sophiris Bio to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

SAN DIEGO, CA and VANCOUVER, BC, Nov. 6, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS), a urology company developing a late-stage, highly...


Oct 09, 2012, 07:00 ET Sophiris Bio Announces 12 Month Follow-Up Data from Phase 2b TRIUMPH Clinical Trial of PRX302 in Patients with Benign Prostatic Hyperplasia

Single administration of PRX302 as a short outpatient procedure provided sustained benefit over 12 months SAN DIEGO, CA and VANCOUVER, Oct. 9,...